Combined angiotensin receptor and neprilysin inhibition therapy for heart failure

    loading  Checking for direct PDF access through Ovid

Abstract

The FDA has approved sacubitril/valsartan, an angiotensin-receptor-neprilysin inhibitor, for the treatment of chronic symptomatic heart failure (stage C) in patients with a left ventricular ejection fraction of 35% or less. This article discusses results from a major clinical trial, PARADIGM-HF, and the role of this new drug in heart failure treatment.

Related Topics

    loading  Loading Related Articles